Exchange: NASDAQ·Updated 07:34 PM EDT
News
all
press releases
First Tracks Biotherapeutics Analysts Increase Their Forecasts After Q2 Results
TRAX reported narrower Q2 loss of 95 cents per share. Analysts raised price targets for the stock, citing potential for ANB033 in immune diseases.read more...
Benzinga
TRAX Stock Hits All-Time High — What's Driving The Super Rally?
According to TheFly, HC Wainwright raised its price target on First Tracks to $44 from $30 while maintaining a ‘Buy’ rating.
Stocktwits
This First Tracks Biotherapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Monday
Top Wall Street analysts changed outlook on top stocks. See analyst ratings page for changes, including upgrades, downgrades, and initiations.read more...
Benzinga

Advertisement|Remove ads.